Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation

Neuroscience Bulletin

Volumn 27, Issue 1, 2011, Pages 53-60

  Lin, Lian Feng ^a   Luo, Huan Min ^a,b,c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c JINAN UNIVERSITY   (China)

Author keywords

A aggregation; Alzheimer's disease; tau hyperphosphorylation; treatment targets

Indexed keywords

AMYLOID BETA PROTEIN; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYMSERINE; DONEPEZIL; HERBACEOUS AGENT; NOBILETIN; PMS 777; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 79952564984     PISSN: 16737067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12264-011-1040-6     Document Type: Short Survey

References (51)

1. Castellani RJ, Zhu XW, Lee HG, Smith MA, Perry G. Molecular pathogenesis of Alzheimer's disease: reductionist versus expansionist approaches. Int J Mol Sci 2009, 10: 1386-1406.
2. Marx J. Alzheimer's disease - A new take on tau. Science 2007, 316: 1416-1417. (Pubitemid 46906589)
3. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 2008, 12: 241-257. (Pubitemid 351430466)
4. Hernandez P, Lee G, Sjoberg M, Maccioni RB. Tau phosphorylation by cdk5 and Fyn in response to amyloid peptide Aβ(25-35): Involvement of lipid rafts. J Alzheimers Dis 2009, 16: 149-156.
5. Korol' TY, Korol' SV, Kostyuk EP, Kostyuk PG. Disruption of calcium homeostasis in Alzheimer's disease. Neurophysiology 2008, 40: 385-392.
6. Kelly BL, Ferreira A. β-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J Biol Chem 2006, 281: 28079-28089. (Pubitemid 44414521)
7. Vaisid T, Barnoy S, Kosower NS. Calpastatin overexpression attenuates amyloid-beta-peptide toxicity in differentiated PC12 cells. Neuroscience 2008, 156: 921-931.
8. 2+ sensor VILIP-1 in hippocampal neurons: A possible crosstalk mechanism for nicotinic receptors. Cell Mol Neurobiol 2009, 29: 273-286.
9. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatric Psychiatry 2003, 18: S1-S5. (Pubitemid 37150472)
10. Chiba T, Yamada M, Sasabe J, Terashita K, Shimoda M, Matsuoka M, et al. Amyloid-beta causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons. Mol Psychiatry 2009, 14: 206-222.
11. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. J Physiol Paris 2006, 99: 172-179.
12. Chin JH, Ma L, MacTavish D, Jhamandas JH. Amyloid-β protein modulates glutamate-mediated neurotransmission in the rat basal forebrain: Involvement of presynaptic neuronal nicotinic acetylcholine and metabotropic glutamate receptors. J Neurosci 2007, 27: 9262-9269. (Pubitemid 47358220)
13. Xu Y, Hou XY, Liu Y, Zong YY. Different protection of K252a and N-acetyl-L-cysteine against amyloid-β peptide-induced cortical neuron apoptosis involving inhibition of MLK3-MKK7-JNK3 signal cascades. J Neurosci Res 2009, 87: 918-927.
14. Sotthibundhu A, Sykes AM, Fox B, Underwood CK, Thangnipon W, Coulson EJ. β-Amyloid(1-42) induces neuronal death through the p75 neurotrophin receptor. J Neurosci 2008, 28: 3941-3946.
15. White JA, Manelli AM, Holmberg KH, Van Eldik LJ, LaDu MJ. Differential effects of oligomeric and fibrillar amyloid-β 1-42 on astrocyte-mediated inflammation. Neurobiol Dis 2005, 18: 459-465. (Pubitemid 40332705)
16. Giovannini MG, Scali C, Prosperi C, Bellucci A, Vannucchi MG, Rosi S, et al. β-Amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: Involvement of the p38MAPK pathway. Neurobiol Dis 2002, 11: 257-274. (Pubitemid 36135690)
17. Salminen A, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Inflammation in Alzheimer's disease: Amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog Neurobiol 2009, 87: 181-194.
18. Walter S, Letiembre M, Liu Y, Heine H, Penke B, Hao W, et al. Role of the toll-like receptor 4 in neuro-inflammation in Alzheimer's disease. Cell Physiol Biochem 2007, 20: 947-956. (Pubitemid 350059737)
19. Jin JJ, Kim HD, Maxwell JA, Li L, Fukuchi KI. Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation 2008, 5: 23.
20. Richard KL, Filali M, Prefontaine P, Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid-β(1-42) and delay the cognitive decline in a mouse model of Alzheimer's disease. J Neurosci 2008, 28: 5784-5793.
21. Lotz M, Ebert S, Esselmann H, Iliev AI, Prinz M, Wiazewicz N, et al. Amyloid-β peptide 1-40 enhances the action of Toll-like receptor-2 and -4 agonists but antagonizes Toll-like receptor-9-induced inflammation in primary mouse microglial cell cultures. J Neurochem 2005, 94: 289-298. (Pubitemid 40995245)
22. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, et al. Induction of Toll-Like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci 2009, 29: 1846-1854.
23. Li J, Huang H, Ezoulin JMM, Gao XL, Massicot F, Dong CZ, et al. Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity. Int J Neuropsychopharmacol 2007, 10: 21-29. (Pubitemid 46122749)
24. Liu W, Yu Y, Wu JH, Luo HM. Gamma-Schisandrin inhibits production of amyloid-β protein 42 in M146L cells. Acta Pharm Sin 2006, 41: 1136-1140.
25. Onozuka H, Nakajima A, Matsuzaki K, Shin RW, Ogino K, Saigusa D, et al. Nobiletin, a citrus flavonoid, improves memory impairment and A beta pathology in a transgenic mouse model of Alzheimer's Disease. J Pharmacol Exp Ther 2008, 326: 739-744.
26. Zheng Y, Cheng XR, Zhou WX, Zhang YX. Gene expression patterns of hippocampus and cerebral cortex of senescence-accelerated mouse treated with Huang-Lian-Jie-Du decoction. Neurosci Lett 2008, 439: 119-124.
27. Li XL, Wang DS, Zhao BQ, Li Q, Qu HY, Zhang T, et al. Effects of Chinese herbal medicine fuzhisan on aged rats. Exp Gerontol 2008, 43: 853-858.
28. Chen GQ, Chen KS, Kobayashi D, Barbour R, Motter R, Games D, et al. Active β-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. J Neurosci 2007, 27: 2654-2662. (Pubitemid 46393609)
29. Mouri A, Noda Y, Hara H, Mizoguchi H, Tabira T, Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB J 2007, 21: 2135-2148. (Pubitemid 47026449)
30. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005, 22: 1942-1950. (Pubitemid 41579384)
31. Kins S, Kurosinski P, Nitsch RM, Götz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 2003, 163: 833-843. (Pubitemid 37040120)
32. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VMY. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001, 168: 402-412. (Pubitemid 32289776)
33. Chohan MO, Khatoon S, Iqbal IG, Iqbal K. Involvement of I-2- (PP2A) in the abnormal hyperphosphorylation of tau and its reversal by Memantine. FEBS Lett 2006, 580: 3973-3979. (Pubitemid 43946883)
34. Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong CX. Dephosphorylation of tau by protein phosphatase 5 - Impairment in Alzheimer's disease. J Biol Chem 2005, 280: 1790-1796.
35. Sun L, Liu SY, Zhou XW, Wang XC, Liu R, Wang Q, et al. Inhibition of protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and impairment of spatial memory retention in rats. Neuroscience 2003, 118: 1175-1182. (Pubitemid 36561203)
36. Luo J, Ma J, Yu DY, Bu F, Zhang W, Tu LH, et al. Infusion of FK506, a specific inhibitor of calcineurin, induces potent tau hyperphosphorylation in mouse brain. Brain Res Bull 2008, 76: 464-468.
37. Lian QY, Ladner CJ, Magnuson D, Lee JM. Selective changes of calcineurin (protein phosphatase 2B) activity in Alzheimer's disease cerebral cortex. Exp Neurol 2001, 167: 158-165. (Pubitemid 32066418)
38. Cuchillo-Ibanez I, Seereeram A, Byers HL, Leung KY, Ward MA, Anderton BH, et al. Phosphorylation of tau regulates its axonal transport by controlling its binding to kinesin. FASEB J 2008, 22(9): 3186-3195.
39. Rankin CA, Sun Q, Gamblin TC. Tau phosphorylation by GSK-3 beta promotes tangle-like filament morphology. Mol Neurodegener 2007, 2: 12.
40. Liao XM, Zhang YC, Wang YP, Wang JZ. The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat. Sci China C Life Sci 2004, 47: 251-257.
41. Sawamura N, Gong JS, Garver WS, Heidenreich RA, Ninomiya H, Ohno K, et al. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem 2001, 276: 10314-10319.
42. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, et al.Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 2001, 60: 1190-1197. (Pubitemid 33117099)
43. Lagalwar S, Guillozet-Bongaarts AL, Berry RW, Binder LI. Formation of phospho-SAPK/JNK is an early event in granules in the hippocampus Alzheimer disease. J Neuropathol Exp Neurol 2006, 65: 455-464. (Pubitemid 44297267)
44. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001, 11: 144-158. (Pubitemid 32198842)
45. Pei JJ, An WL, Cowburn RF, Grundke-Iqbal I, Iqbal K, Winblad B. Involvement of aberrant regulation of PI3K and MAPK cascades in AD Tau phosphorylation. Neurobiol Aging 2004, 25: S90-S90.
46. Baki L, Shioi J, Wen P, Shao ZP, Schwarzman A, Gama-Sosa M, et al. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 2004, 23: 2586-2596. (Pubitemid 38988230)
47. Ryder J, Yuan S, Ni BH. Akt/GSK3 beta serine/threonine kinases: evidence for a signalling pathway mediated by familial Alzheimer's disease mutations. Cell Signal 2004, 16: 187-200. (Pubitemid 37431168)
48. Chatterjee S, Sang TK, Lawless GM, Jackson GR. Dissociation of tau toxicity and phosphorylation: role of GSK-3 beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet 2009, 18: 164-177.
49. Poppek D, Keck S, Ermak G, Jung T, Stolzing A, Ullrich O, et al. Phosphorylation inhibits turnover of the tau protein by the proteasome: influence of RCAN1 and oxidative stress. Biochem J 2006, 400: 511-520. (Pubitemid 44974463)
50. Hernandez F, Avila J. Tau aggregates and tau pathology. J Alzheimers Dis 2008, 14: 449-452.
51. Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann N Y Acad Sci 2005, 1056: 430-449. (Pubitemid 43030997)